Riwia holds a Bachelor’s degree in Medical Microbiology and a Master’s degree in Immunology from Imperial College London. Her MSc thesis, titled ‘Characterising the Role of MALT1 Paracaspase Activity in Psoriatic CARD14 Signalling’, provided extensive experience in in vitro assay development, mammalian cell culture, and analytical methodologies widely applied within regulated laboratory environments.
At Test Labs, Riwia has played a key role in the introduction and establishment of biocompatibility testing in accordance with ISO 10993 standards. She helped lead the implementation of ISO 10993-5 cytotoxicity testing within the laboratory and supported validation of the method under Good Laboratory Practice (GLP). This involved maintaining cell culture systems, executing validated protocols, and embedding quality-controlled processes to meet regulatory requirements for medical device evaluation.
Alongside her work in biocompatibility, Riwia conducts UKAS-accredited ISO 17025 disinfectant efficacy testing to European standards. Her background in microbiology and immunology enables her to confidently deliver both antimicrobial efficacy studies and cell-based medical device evaluations within a fully regulated framework.
Riwia is a dedicated and hard-working scientist whose combined expertise in microbiology, immunology, and regulatory compliance supports the development, validation, and delivery of high-quality testing across both disinfectant efficacy and medical device biocompatibility.